Kalvista Pharmaceuticals Inc (KALV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 04/30
| 04-2018 | 01-2018 | 10-2017 | 07-2017 | 04-2017 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 51,055 | 58,678 | 28,128 | 26,456 | 30,950 |
| Receivables | 6,834 | 5,029 | 4,611 | 2,895 | 2,547 |
| TOTAL | $59,380 | $65,710 | $34,139 | $30,192 | $34,198 |
| Non-Current Assets | |||||
| PPE Net | 1,836 | 774 | 602 | 592 | 97 |
| Other Non-Current Assets | 173 | 173 | 0 | 0 | 50 |
| TOTAL | $2,009 | $947 | $602 | $592 | $147 |
| Total Assets | $61,389 | $66,657 | $34,741 | $30,784 | $34,345 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,433 | 1,575 | 1,040 | 1,943 | 1,153 |
| Accrued Expenses | 3,087 | 2,290 | 2,253 | 1,692 | 1,865 |
| TOTAL | $23,216 | $24,083 | $3,513 | $3,837 | $3,018 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 18,475 | 19,996 | N/A | N/A | N/A |
| TOTAL | $10,920 | $14,006 | $149 | $213 | $N/A |
| Total Liabilities | $34,136 | $38,089 | $3,662 | $4,050 | $3,018 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | N/A | 10,796 | 10,785 | 9,713 | N/A |
| Common Shares | 11 | 11 | 11 | 10 | 10 |
| Retained earnings | -71,660 | -71,003 | -65,769 | -60,784 | -55,855 |
| Other shareholders' equity | -1,109 | -136 | -2,571 | -2,528 | -2,643 |
| TOTAL | $27,253 | $28,568 | $31,079 | $26,734 | $31,327 |
| Total Liabilities And Equity | $61,389 | $66,657 | $34,741 | $30,784 | $34,345 |